Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
Belantamab mafodotin has potential to be the first anti-BCMA treatment available to patients
-
Dovato (dolutegravir/lamivudine), the once-daily, single-pill, 2-drug regimen for the treatment of HIV-1 infection, granted marketing approval by Japan Ministry of Health, Labour and Welfare
ViiV Healthcare, the global specialist HIV company announced that it has obtained approval of Dovato.
-
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir.
-
Deborah Waterhouse, CEO of ViiV Healthcare, to join GSK Corporate Executive Team (CET)
GlaxoSmithKline plc today announced that Deborah Waterhouse, CEO of ViiV Healthcare, will join GSK’s Corporate Executive Team
-
GSK completes divestment of rabies and tick-borne encephalitis vaccines to Bavarian Nordic
GlaxoSmithKline plc today announced the completion of the divestment of Rabipur (tradename Rabavert in the US) to Bavarian Nordic.
-
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
ViiV Healthcare received a CRL from the FDA regarding its application for cabotegravir and rilpivirine.
-
GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis
BLISS-LN achieves primary endpoint and all major secondary endpoints. On-track for regulatory submission during the first half of 2020.
-
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
Today announced treatment with the investigational single-agent belantamab mafodotin.
-
GSK Consumer Healthcare nutritional products divestment
GSK Consumer Healthcare nutritional products divestment
-
ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV
If approved, DTG will be the first integrase inhibitor available as a dispersible tablet for children living with HIV.
-
ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
ViiV Healthcare completed submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA).
-
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb”.
-
Nucala (mepolizumab) is the first treatment to show a significant reduction in flares for patients with Hypereosinophilic Syndrome (HES)
Positive data from a pivotal study supports new regulatory filing in HES
-
EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV
Data presentations expand understanding of ViiV Healthcare’s pipeline for heavily treatment-experienced populations.
-
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*)
GSK delivers sales of £9.4 b +16% AER, +11% CER (Pro-forma +6% CER*) Total EPS 31.4p +9% AER, -1% CER; Adjusted EPS 38.6p +9% AER, +1% CER
-
Intravenous Benlysta is the first biologic treatment to be approved for children with lupus in Europe
European Commission has made a decision to extend to children five years and older, the existing adult indication for intravenous Benlysta
-
GSK candidate vaccine demonstrates sustained level of protection against active pulmonary tuberculosis
Analysis of phase IIb study published in the New England Journal of Medicine, presented at the 50th Union World Conference on Lung Health.
-
GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin
First in a new chemical class of antibiotic with a mechanism of action distinct from any currently approved antibiotic.
-
GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic
GSK to receive upfront payment of approximately EUR301 million and milestone payments for a total consideration of up to EUR955 million
-
Global Fund Replenishment - 2019 media statement
The Global Fund, world's largest financier of 3 of the deadliest diseases worldwide, AIDS, TB, and malaria, has helped save 27 million lives
